• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Life Sciences | News, Analysis, Insights - HIT Consultant

Clarapath Acquires AI-Powered Digital Pathology Platform Crosscope

by Fred Pennic 03/09/2023 Leave a Comment

Clarapath Acquires AI-Powered Digital Pathology Platform Crosscope

What You Should Know: - Clarapath, a robotics company aimed at catalyzing change in the way pathology laboratories process human and animal tissue acquires Mountain View, CA-based Crosscope. Financial details of the acquisition were not disclosed. - Crosscope is a digital pathology company with a turnkey imaging solution providing best-in-class workflow tools and slide management along with artificial intelligence (AI) and machine learning (ML) technology to assist pathologists with better
Read More

C2i Genomics, Riken Genesis Expands AI-Powered Whole-Genome MRD Cancer Detection Across Japan

by Strategic Partnerships 03/02/2023 Leave a Comment

C2i Genomics, Karkinos Healthcare Partner to Bring AI-Powered Cancer R&D to India

What You Should Know: - C2i Genomics, a cancer intelligence company, today announced a collaboration with Riken Genesis Co., Ltd. (RG), a company specializing in providing the service of personalized medicine based on contract analysis of next-generation sequencing and exomes. The two companies have entered a collaboration agreement to bring MRD cancer monitoring to Japan for pharmaceutical and clinical research.  - Under this agreement, RG will work with C2i Genomics to commercialize
Read More

Eli Lilly Cuts Insulin Prices by 70%, Caps Patient Costs at $35 Per Month

by Jasmine Pennic 03/01/2023 Leave a Comment

Eli Lilly Cuts Insulin Prices by 70%, Caps Patient Costs at $35 Per Month

What You Should Know: - Eli Lilly and Company today announced price reductions of 70% for its most commonly prescribed insulins and an expansion of its Insulin Value Program that caps patient out-of-pocket costs at $35 or less per month at participating retail pharmacies.  - The historic price cut makes it easier to access Lily insulin for Americans who may have difficulty navigating a complex healthcare system that may keep them from getting affordable
Read More

M&A: ArisGlobal to Acquire Amplexor Life Sciences

by Jasmine Pennic 03/01/2023 Leave a Comment

M&A: ArisGlobal to Acquire Amplexor Life Sciences

What You Should Know: - ArisGlobal, the leading provider of life sciences software designed to automate core drug development functions, acquired Amplexor Life Sciences, a global provider of regulatory, quality, and safety software solutions. Financial details of the acquisition were not disclosed. - This combined product ecosystem provides a new opportunity for life sciences companies, bringing together best-in-breed solutions to form a cohesive solution serving customers’
Read More

OpenText Partners with Bayer to Digitize B2B Operations

by Strategic Partnerships 03/01/2023 Leave a Comment

OpenText Partners with Bayer to Digitize B2B Operations

What You Should Know: - Global tech anchor, OpenText™ announced its collaboration with healthcare and agricultural leader, Bayer, to simplify its digital operations.  - This partnership echoes the current trend which sees legacy companies adopting more robust digital solutions to elevate their businesses and free up time to focus on other priorities.  - Bayer has strategically chosen OpenTextTM Business Network Cloud Enterprise, which will be tapped for strategic B2B
Read More

Why Clinical Data Research Needs a Makeover in 2023

by Anne Kim, Co-Founder and CEO of Secure AI Labs (SAIL) 03/01/2023 Leave a Comment

Why Clinical Data Research Needs a Makeover

Clinical research is only as good and thorough as the data that’s available — and we need to do a better job of making that data accessible for researchers.  Unfortunately, the majority of clinical data is based on the same clinical sites and makes conclusions off a limited range of data points. Clinical trials often exclude minorities, rare disease subtypes and other underrepresented populations. Changing the way we gather and share clinical data isn’t easy. Hospitals, biobanks and
Read More

Tempus, Pfizer Partner to Advance Oncology Therapeutic Development

by Fred Pennic 02/28/2023 Leave a Comment

Tempus, Pfizer Partner to Advance Oncology Therapeutic Development

What You Should Know: - Today, the AI-powered genetic testing and precision medicine company Tempus announced that it has signed a significant strategic agreement with Pfizer to more precisely gather insights that will inform novel drug discovery and development in oncology. - Through this collaboration, Pfizer has access to Tempus’ AI-enabled platform and its library of de-identified, multimodal data to uncover insights that will power therapeutic development in oncology. -
Read More

Stratasys, Ricoh Partner to Provide On-Demand 3D-Printed Anatomic Models for Hospitals and Clinics

by Jasmine Pennic 02/28/2023 Leave a Comment

Stratasys, Ricoh Partner to Provide On-Demand 3D-Printed Anatomic Models for Hospitals and Clinics

What You Should Know: - Stratasys Ltd. today announced they have signed another agreement with RICOH USA to provide on-demand 3D-printed anatomic models for clinical settings. - The demand for additive manufacturing within the healthcare industry is continuously growing, and according to Grandview Research, the global healthcare additive manufacturing market size was valued at USD 1.6 billion in 2021 and is expected to expand at a compound annual growth rate of 22.6% from 2022 to 2030.
Read More

What Impact Could AI Have On Genetic Testing?

by Dr Rocío Acuña Hidalgo, co-founder and CTO at Nostos Genomics 02/27/2023 Leave a Comment

What Impact Could AI Have On Genetic Testing?

The sequencing and analysis of human DNA have advanced significantly since the initial draft of a human genome that was published as part of the Human Genome Project. With DNA sequencing becoming increasingly cost-effective, the market for genetic testing is growing at an accelerating rate – the market for Next Generation Sequencing (NGS) services has an estimated annual growth of 18.3% from 2022 to 2030. AI presents a range of possibilities for this rapidly growing field, and in this article,
Read More

ObvioHealth Launches Digital Therapeutics API for Clinical Trials

by Fred Pennic 02/24/2023 Leave a Comment

ObvioHealth Launches Digital Therapeutics API for Clinical Trials

What You Should Know: - ObvioHealth launches proprietary application programming interface (API) tailored specifically for digital therapeutics (DTx) clinical trials. - ObvioHealth’s API ensures tight integration between the digital therapeutic and the ObvioGo platform, providing sponsors with accurate data to correlate efficacy with adherence to the DTx. In addition, ObvioGo’s integration reduces participant task duplication because—in most cases—outcomes can be passively captured
Read More

  • Previous Page
  • Go to page 1
  • Interim pages omitted …
  • Go to page 47
  • Go to page 48
  • Go to page 49
  • Go to page 50
  • Go to page 51
  • Interim pages omitted …
  • Go to page 91
  • Next Page

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Interview

Reach7 Diabetes Studios Founder Chun Yong on Reimagining Chronic Care with a Concierge Medical Model

Most-Read

Bayer Exits Radiology AI Market, Discontinuing Calantic and Blackford

Bayer Exits Radiology AI Market, Discontinuing Calantic and Blackford

Oracle Health Launches AI Center of Excellence for Healthcare

Oracle Health Launches AI Center of Excellence for Healthcare

Particle Health Addresses Integration to Epic Data Despite Dispute

US Court Allows Particle’s Antitrust Claims Against Epic to Proceed

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Preparing for the ‘Big Beautiful Bill’: How Digitization Can Streamline Medicaid Eligibility & Social Care Delivery

Preparing for the ‘Big Beautiful Bill’: How Digitization Can Streamline Medicaid Eligibility & Social Care Delivery

Evernorth Health Services Invests $3.5B in Shields Health Solutions

Evernorth Health Services Invests $3.5B in Shields Health Solutions

KLAS Report: Oracle Health Faces Customer Losses and Declining Satisfaction

KLAS Report: Oracle Health Faces Customer Losses and Declining Satisfaction

Tempus AI Acquires Digital Pathology Leader Paige for $81.25M

M&A:Tempus AI Acquires Digital Pathology Leader Paige for $81.25M

Mira Launches Ultra4™, the First At-Home Hormone Monitor with Lab-Quality Insights

Femtech: Mira Launches Ultra4™, the First At-Home Hormone Monitor with Lab-Quality Insights

How Healthcare CIOs Can Solve the Unstructured Data Crisis and Reduce Storage Costs

How Healthcare CIOs Can Solve the Unstructured Data Crisis and Reduce Storage Costs

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |